- Home
- IROQ vs CNTX Comparison
IROQ vs CNTX Comparison
Compare IROQ & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROQ
- CNTX
- Stock Information
- Founded
- IROQ 1883
- CNTX 2015
- Country
- IROQ United States
- CNTX United States
- Employees
- IROQ N/A
- CNTX N/A
- Industry
- IROQ Savings Institutions
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- IROQ Finance
- CNTX Health Care
- Exchange
- IROQ Nasdaq
- CNTX Nasdaq
- Market Cap
- IROQ 75.0M
- CNTX 78.0M
- IPO Year
- IROQ 2011
- CNTX 2021
- Fundamental
- Price
- IROQ N/A
- CNTX $0.64
- Analyst Decision
- IROQ
- CNTX Strong Buy
- Analyst Count
- IROQ 0
- CNTX 5
- Target Price
- IROQ N/A
- CNTX $5.50
- AVG Volume (30 Days)
- IROQ 1.6K
- CNTX 312.3K
- Earning Date
- IROQ 08-28-2025
- CNTX 08-06-2025
- Dividend Yield
- IROQ 1.63%
- CNTX N/A
- EPS Growth
- IROQ 69.23
- CNTX N/A
- EPS
- IROQ 1.05
- CNTX N/A
- Revenue
- IROQ $25,099,000.00
- CNTX N/A
- Revenue This Year
- IROQ N/A
- CNTX N/A
- Revenue Next Year
- IROQ N/A
- CNTX N/A
- P/E Ratio
- IROQ $23.43
- CNTX N/A
- Revenue Growth
- IROQ 12.02
- CNTX N/A
- 52 Week Low
- IROQ $16.34
- CNTX $0.49
- 52 Week High
- IROQ $25.76
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- IROQ 51.14
- CNTX 46.34
- Support Level
- IROQ $24.35
- CNTX $0.62
- Resistance Level
- IROQ $24.98
- CNTX $0.70
- Average True Range (ATR)
- IROQ 0.28
- CNTX 0.04
- MACD
- IROQ -0.02
- CNTX 0.01
- Stochastic Oscillator
- IROQ 74.30
- CNTX 42.86
About IROQ IF Bancorp Inc.
IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.